{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:35:42Z","timestamp":1787164542824,"version":"build-2736575974"},"reference-count":61,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Ferric carboxymaltose (FCM) has been shown to achieve rapid replenishment of iron stores and correction of anaemia in various populations with iron deficiency. A decrease in serum phosphate (PO43\u2212) levels, which in most cases is asymptomatic, has been reported with IV iron preparations. Hypophosphataemia (HP) is a known adverse drug reaction with FCM. This post hoc pooled analysis investigates the frequency, duration, risk factors, and clinical signs of HP as reported in interventional clinical trials with FCM. Pooled data from subjects enrolled across 45 clinical trials in different therapy areas were included. A three-step adjudication process was utilised to identify adverse events of HP. Stratified analyses by therapy group and stepwise logistic regression analysis were used to identify predictors of HP. This pooled analysis confirms that FCM is associated with increased rates of serum PO43\u2212 lowering, but mean serum PO43\u2212 values were seen to recover at Week 4 and further recover at Week 8. Among all subjects receiving FCM therapy (n = 6879), 41.4% (n = 2847) reached a PO43\u2212 nadir value &lt;2.5 mg\/dL at any point on study and 0.7% (n = 49) reached a nadir &lt;1 mg\/dL. Although gastroenterology and women\u2019s health subjects were identified to be at higher risk, occurrence of severe HP (&lt;1 mg\/dL [0.3 mmol\/L]) following FCM administration was not observed to be common among subjects in these studies. Furthermore, there was no correlation between laboratory serum PO43\u2212 values and the occurrence of reported adverse events related to low PO43\u2212 levels.<\/jats:p>","DOI":"10.3390\/jcm9113587","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T09:09:30Z","timestamp":1604653770000},"page":"3587","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose"],"prefix":"10.3390","volume":"9","author":[{"given":"Giuseppe","family":"Rosano","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, IRCCS San Raffaele Pisana, 00166 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingolf","family":"Schiefke","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, Diabetology and Endocrinology, Klinikum St. Georg, 04129 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo-Michael","family":"G\u00f6hring","sequence":"additional","affiliation":[{"name":"Clinical Development, Vifor Pharma, 8152 Glattbrugg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Fabien","sequence":"additional","affiliation":[{"name":"Biometrics, Vifor Pharma, 8152 Glattbrugg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3833-6717","authenticated-orcid":false,"given":"Stefano","family":"Bonassi","sequence":"additional","affiliation":[{"name":"Department of Human Sciences and Quality of Life Promotion, San Raffaele University, 00166 Rome, Italy"},{"name":"Unit of Clinical and Molecular Epidemiology, IRCCS San Raffaele Pisana, 00166 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3558-3341","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Stein","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Clinical Nutrition, DGD Clinics Sachsenhausen, 60594 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.amjmed.2005.02.014","article-title":"Hypophosphatemia: An update on its etiology and treatment","volume":"118","author":"Gaasbeek","year":"2005","journal-title":"Am. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/0004563214521399","article-title":"Phosphate homeostasis and disorders","volume":"51","author":"Manghat","year":"2014","journal-title":"Ann. Clin. Biochem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1210\/jc.2011-1319","article-title":"Approach to the hypophosphatemic patient","volume":"97","author":"Imel","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_4","unstructured":"Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., Dungan, K., Grossman, A., Hershman, J.M., Hofland, H.J., and Kaltsas, G. (2000). Primary Disorders of Phosphate Metabolism. Endotext, MDText.com, Inc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0960-8966(93)90063-P","article-title":"Oral phosphate supplements reverse skeletal muscle abnormalities in a case of chronic fatigue with idiopathic renal hypophosphatemia","volume":"3","author":"Land","year":"1993","journal-title":"Neuromuscul. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM197710272971702","article-title":"Effect of hypophosphatemia on myocardial performance in man","volume":"297","author":"Wheeler","year":"1977","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/0002-9343(92)90740-3","article-title":"Prevalence and predictors of rhabdomyolysis in patients with hypophosphatemia","volume":"92","author":"Singhal","year":"1992","journal-title":"Am. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/PEC.0b013e3181c399f6","article-title":"Hypophosphatemia-induced seizure in a child with diabetic ketoacidosis","volume":"25","year":"2009","journal-title":"Pediatr. Emerg. Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1111\/j.1432-2277.2011.01393.x","article-title":"Hemolytic anemia associated with severe hypophosphatemia in a renal transplant recipient","volume":"25","author":"Poesen","year":"2012","journal-title":"Transpl. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11914-015-0259-y","article-title":"Hypophosphatemic rickets: Lessons from disrupted FGF23 control of phosphorus homeostasis","volume":"13","author":"Goldsweig","year":"2015","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1053\/j.ajkd.2012.03.024","article-title":"Approach to treatment of hypophosphatemia","volume":"60","author":"Felsenfeld","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"ref_12","first-page":"365","article-title":"Severe hypophosphatemia in hospitalized patients","volume":"16","author":"Camp","year":"1990","journal-title":"Miner. Electrolyte Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/cc9215","article-title":"Treatment of hypophosphatemia in the intensive care unit: A review","volume":"14","author":"Geerse","year":"2010","journal-title":"Crit. Care"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wang, L., Xiao, C., Chen, L., Zhang, X., and Kou, Q. (2019). Impact of hypophosphatemia on outcome of patients in intensive care unit: A retrospective cohort study. BMC Anesthesiol., 19.","DOI":"10.1186\/s12871-019-0746-2"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jemermed.2003.12.002","article-title":"A case of near-fatal hypophosphatemia","volume":"26","author":"Roldan","year":"2004","journal-title":"J. Emerg. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-4684-4259-5_26","article-title":"Effects of phosphate depletion on the myocardium","volume":"151","author":"Brautbar","year":"1982","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_17","unstructured":"Vifor Pharma UK Ltd. (2020, November 04). Ferinject (ferric carboxymaltose) summary of product characteristics. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/5910\/smpc#gref."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/ndt\/gfv293","article-title":"A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia","volume":"31","author":"Kalra","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000487368","article-title":"Associations Between Intravenous Iron, Inflammation and FGF23 in Non-Dialysis Patients with Chronic Kidney Disease Stages 3\u20135","volume":"43","author":"Nowicki","year":"2018","journal-title":"Kidney Blood Press. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"468675","DOI":"10.1155\/2015\/468675","article-title":"Intravenous iron administration and hypophosphatemia in clinical practice","volume":"2015","author":"Hardy","year":"2015","journal-title":"Int. J. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","article-title":"FGF23 at the crossroads of phosphate, iron economy and erythropoiesis","volume":"16","author":"Edmonston","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","article-title":"Coupling fibroblast growth factor 23 production and cleavage: Iron deficiency, rickets, and kidney disease","volume":"23","author":"Wolf","year":"2014","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40264-019-00888-1","article-title":"Drug-Induced Hypophosphatemia: Current Insights","volume":"43","author":"Megapanou","year":"2019","journal-title":"Drug Saf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1210\/jc.2008-2396","article-title":"FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: A prospective study","volume":"94","author":"Schouten","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/2042018816678363","article-title":"Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: A report of two cases and review of the literature","volume":"8","author":"Bishay","year":"2017","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_27","unstructured":"Vifor Pharma Ltd. Data on File."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40265-018-0885-7","article-title":"Ferric Carboxymaltose: A Review in Iron Deficiency","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40265-014-0332-3","article-title":"Ferric carboxymaltose: A review of its use in iron deficiency","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40261-015-0361-z","article-title":"Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials","volume":"36","author":"Rognoni","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/apt.14043","article-title":"Systematic review with network meta-analysis: Comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease","volume":"45","author":"Aksan","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40264-018-0769-5","article-title":"Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase between 2014 and 2017","volume":"42","author":"Ehlken","year":"2019","journal-title":"Drug Saf."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40264-019-00868-5","article-title":"Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) before and after Implementation of Risk Minimization Measures","volume":"43","author":"Nathell","year":"2020","journal-title":"Drug Saf."},{"key":"ref_34","unstructured":"Common Terminology Criteria for Adverse Events (2020, November 04). Version 5.0: National Institute of Health, National Cancer Institute, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"ref_35","unstructured":"Common Terminology Criteria for Adverse Events (2020, November 04). Version 4.0: National Institute of Health, National Cancer Institute, Available online: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40620-014-0083-y","article-title":"Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease","volume":"28","author":"Chand","year":"2015","journal-title":"J. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12185-018-2501-8","article-title":"Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: A multi-center, randomized, open-label noninferiority study","volume":"109","author":"Ikuta","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.jacc.2018.03.448","article-title":"High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia","volume":"71","author":"Stohr","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/bcp.13189","article-title":"Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions","volume":"83","author":"Bager","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/apt.15386","article-title":"Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside","volume":"50","author":"Detlie","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S243462","article-title":"Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review","volume":"16","author":"Glaspy","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1053\/j.gastro.2016.09.050","article-title":"Blood and Bone Loser","volume":"152","author":"Schaefer","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jbmr.3319","article-title":"Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures after Iron Substitution in Inflammatory Bowel Disease: A Case Report","volume":"33","author":"Bartko","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jbmr.3369","article-title":"Iron Supplementation-Induced Phosphaturic Osteomalacia: FGF23 is the Culprit","volume":"33","author":"Urbina","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Klein, K., Asaad, S., Econs, M., and Rubin, J.E. (2018). Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Rep., 2018.","DOI":"10.1136\/bcr-2017-222851"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/jbmr.3372","article-title":"Re: Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report","volume":"33","author":"Tournis","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4045\/tidsskr.12.0494","article-title":"Uncommon adverse effect of a common medication","volume":"133","author":"Moore","year":"2013","journal-title":"Tidsskrift den Norske Legeforening"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/jgh3.12150","article-title":"Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose","volume":"3","author":"Fang","year":"2019","journal-title":"JGH Open"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Roman-Gimeno, S., Ortez-Toro, J.J., Peteiro-Miranda, C.M., Sanz-Martin, B., and Urdaniz-Borque, R. (2020). Case report: A rare cause of severe hypophosphatemia. Ann. Endocrinol.","DOI":"10.1016\/j.ando.2020.04.008"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00198-019-05190-5","article-title":"The association between chronic kidney disease, falls, and fractures: A systematic review and meta-analysis","volume":"31","author":"Goto","year":"2020","journal-title":"Osteoporos. Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jbm4.10117","article-title":"Rethinking Bone Disease in Kidney Disease","volume":"2","author":"Damasiewicz","year":"2018","journal-title":"JBMR Plus"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: An emerging complication","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_54","first-page":"1628","article-title":"A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy","volume":"33","author":"Huang","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wolf, M., Chertow, G.M., Macdougall, I.C., Kaper, R., Krop, J., and Strauss, W. (2018). Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight, 3.","DOI":"10.1172\/jci.insight.124486"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s11255-017-1558-2","article-title":"Hypophosphatemia: Nutritional status, body composition, and mortality in hemodialysis patients","volume":"49","author":"Garagarza","year":"2017","journal-title":"Int. Urol. Nephrol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e6493","DOI":"10.1097\/MD.0000000000006493","article-title":"Adult-onset hypophosphatemic osteomalacia associated with Sjogren syndrome: Clinical case report","volume":"96","author":"Shen","year":"2017","journal-title":"Medicine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1053\/gast.2003.50106","article-title":"AGA technical review on osteoporosis in gastrointestinal diseases","volume":"124","author":"Bernstein","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/gut.40.3.313","article-title":"Bone mineral density is reduced in patients with Crohn\u2019s disease but not in patients with ulcerative colitis: A population based study","volume":"40","author":"Jahnsen","year":"1997","journal-title":"Gut"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJM199912233412607","article-title":"Disorders of iron metabolism","volume":"341","author":"Andrews","year":"1999","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3587\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:30:22Z","timestamp":1760178622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":61,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["jcm9113587"],"URL":"https:\/\/doi.org\/10.3390\/jcm9113587","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]}}}